Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody disease.

Dos Passos GR. et al, (2020), J Neurol Sci, 415

Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective cohort study.

Arun T. et al, (2020), Neurology

Modified Delphi study of decision-making around treatment sequencing in relapsing-remitting multiple sclerosis.

Piena MA. et al, (2020), Eur J Neurol

Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.

Tsymala I. et al, (2020), Acta Neuropathol Commun, 8

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies.

Yeo T. et al, (2020), Ann Clin Transl Neurol

International multicenter examination of MOG antibody assays

Reindl M. et al, (2020), Neurology - Neuroimmunology Neuroinflammation, 7, e674 - e674

Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.

Rodríguez Cruz PM. et al, (2020), Hum Mutat, 41, 619 - 631

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Chataway J. et al, (2020), Lancet Neurol, 19, 214 - 225

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.

Sastre-Garriga J. et al, (2020), Nat Rev Neurol

242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019.

Munot P. et al, (2020), Neuromuscul Disord

Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.

Geraldes R. et al, (2020), J Neurol Neurosurg Psychiatry

International multicenter examination of MOG antibody assays.

WATERS P., (2020), Neurology, Neuroimmunology and Neuroinflammation

Prodromal headache in MOG-antibody positive optic neuritis.

Asseyer S. et al, (2020), Mult Scler Relat Disord, 40

DEMOGRAPHIC, CLINICAL AND PARACLINICAL FEATURES IN A SUBGROUP OF PATIENTS WITH NMOSD

Wegehaupt T. et al, (2019), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 90, E63 - E63

DISTINGUISHING NEUROSARCOIDOSIS FROM MULTIPLE SCLEROSIS BASED ON CEREBROSPINAL FLUID ANALYSIS: A RETROSPECTIVE COHORT STUDY

Arun T. et al, (2019), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 90, E8 - E9

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Yamamura T. et al, (2019), N Engl J Med, 381, 2114 - 2124

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling.

Yeo T. et al, (2019), Neurol Neuroimmunol Neuroinflamm, 6

The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.

Asnafi S. et al, (2019), Mult Scler Relat Disord, 37

β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.

Vanhaesebrouck AE. et al, (2019), Brain

Efficacy of satralizumab in subgroups of patients in SAkuraSky: A phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD)

Yamamura T. et al, (2019), JOURNAL OF THE NEUROLOGICAL SCIENCES, 405

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?